您的位置:首页 > 产品中心 > Tumor Necrosis Factor Soluble Receptor II (TNF sRII)/Fc Chimera human
产品中心
Tumor Necrosis Factor Soluble Receptor II (TNF sRII)/Fc Chimera human

| 产品编号: | 4096272 |
| 规格: | >95% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder, suitable for cell culture |
| 包装规格: | 50 μG |
| 产品类别: | 进口试剂 |
| 品牌: | Sigma-Aldrich |
| 优惠价: | 立即咨询 |
基本信息
| MDL number | MFCD02689206 |
| NACRES | NA.32 |
| Application【应用】 | Tumor Necrosis Factor Soluble Receptor II (TNF sRII)/Fc Chimera human can be used as a test compound for analyzing the interaction between tumor necrosis factor (TNF) and its two soluble receptors by using surface plasmon resonance (SPR) technique. |
| Biochem/physiol Actions【生化/生理作用】 | Tumor Necrosis Factor Soluble Receptor II (TNF sRII)/Fc Chimera human belongs to TNF family of receptors and mediates the metabolic effects of TNF-α. Tumor Necrosis Factor Soluble Receptor II blocks the TNF-α-induced apoptosis and hence regulates the TNF-α function. It also has a pivotal role in neutralizing the biological activities of both TNF-α and TNF-β. |
| Physical form【外形】 | Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline |
| Analysis Note【分析说明】 | The biological activity is measured by its ability to neutralize the TNF-α mediated cytotoxicity in mouse L-929 cells in the presence of the metabolic inhibitor actinomycin D. |
产品性质
| Quality Level【质量水平】 | 200 |
| biological source【生物来源】 | human |
| recombinant【重组】 | expressed in NSO cells |
| Assay【测定】 | >95% (SDS-PAGE) |
| form【形式】 | lyophilized powder |
| potency【效能】 | 0.004-0.016 mg per mL ED50 |
| mol wt【分子量】 | 52.6 kDa |
| packaging【包装】 | pkg of 50 μg |
| storage condition【储存条件】 | avoid repeated freeze/thaw cycles |
| technique(s) | cell culture | mammalian: suitable |
| impurities【杂质】 | endotoxin, tested |
| UniProt accession no.【UniProt登记号】 | P20333 |
| storage temp.【储存温度】 | −20℃ |
| Gene Information | human ... TNFRSF1B(7133) |
安全信息
| Storage Class Code【储存分类代码】 | 13 - Non Combustible Solids |
| WGK | WGK 3 |





